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HIV-infected patients on highly active antiretroviral therapy (HAART) have persistently decreased cytomegalovirus (CMV)-specific
proliferative responses [lymphocyte proliferation assay (LPA)] in spite of increases in CD4+ T cell counts. Here we demonstrate an
association between apoptosis of unstimulated peripheral blood mononuclear cells (uPBMC) and decreased CMV-LPA. HAART recipients
had more apoptosis of uPBMC than controls when measured by caspases 3, 8, and 9 activities and by annexin V binding. Patients with
undetectable HIV replication maintained significantly higher apoptosis of CD4+ and CD14+ cells compared to controls. CMV-LPA
decreased with higher apoptosis of uPBMC in patients only. This association was independent of CD4+ cell counts or HIV replication.
Furthermore, rescuing PBMC from apoptosis with crmA, but not with TRAIL- or Fas-pathway blocking agents or with other caspase
inhibitors, increased CMV-LPA in HAART recipients. This effect was not observed in uninfected controls, further indicating that the down
regulatory effect of apoptosis on cell-mediated immunity (CMI) was specifically associated with the HIV-infected status.
D 2004 Elsevier Inc. All rights reserved.
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Human immunodeficiency virus (HIV) preferentially
destroys CD4+ T lymphocytes and interferes with other
regulatory mechanisms of the immune system, thereby
weakening defenses against infectious agents (Fauci et al.,
1991). Highly active antiretroviral therapy (HAART)
restores CD4+ T cell numbers and decreases the incidence
of opportunistic infections including cytomegalovirus
(CMV) (Autran et al., 1997; Hammer et al., 1997; Palella
et al., 1998). Although anti-CMV therapy can be generally
discontinued in patients who achieve CD4+ counts z100
cells/Al after z3 months of HAART (Jabs et al., 1998;
Macdonald et al., 1998; Whitcup et al., 1999), CMV eye0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: Adriana.Weinberg@uchsc.edu (A. Weinberg).lesions occasionally occur in these patients despite high
CD4+ cell numbers, usually in association with abnormal
CMV-specific cell-mediated immunity (CMI) (Jacobson et
al., 2000; Karavellas et al., 1998, 1999; Zegans et al., 1998).
Other findings also indicate that immune reconstitution in
HAART recipients is incomplete. These include observa-
tions such as incomplete recovery of CMI to varicella–
zoster virus (Weinberg et al., 2004b) and to candida
(Weinberg et al., 2004a) and decreased immune responses
to immunizations (Lederman et al., 2003; Valdez et al.,
2002; Weinberg et al., 2003a). Taken together, these
findings suggest that HAART recipients might benefit from
additional interventions to boost their immune responses.
We previously showed that CMV-specific proliferative
responses [lymphocyte proliferation assay (LPA)] are down
regulated in HIV-infected patients on HAART to a greater
extent than other CMI components, such as IFNg produc-
tion (Weinberg et al., 2001). We and others have shown that
the down regulation of CMV-LPA in HIV-infected patients04) 313–321
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Fig. 1. Apoptosis measured by caspase activity in unstimulated PBMC from
HIV-infected patients and uninfected controls. Data were derived from 18
HIV-infected donors and nine uninfected controls. There were significant
differences between HIV-infected patients and controls with respect to
caspase 3 activity. Caspases 8 and 9 results were not conducive to statistical
analyses because the means and SD in healthy controls equaled 0.
A. Weinberg et al. / Virology 330 (2004) 313–321314on HAART is associated with deficient IL2 production
(Iyasere et al., 2003; Weinberg et al., 2003b). In vitro CD8+
T cell depletion partially restored CMV-specific prolifer-
ation, which led to the hypothesis that nonspecific regu-
latory mechanisms associated with chronic HIV infection
contributed to the LPA deficit.
In this study, we examine the role of apoptosis in the
down regulation of CMI in HAART recipients and the effect
of interventions that rescue peripheral blood mononuclear
cells (PBMC) from programmed cell death. Apoptosis,
which remains elevated in HIV-infected patients on HAART
(de Oliveira Pinto et al., 2002), is used by the host to
modulate immune responses and avoid excessive activation
(Bouillet et al., 2002; Janssens et al., 2003; Khaled and
Durum, 2002). This involves both the death receptor and the
mitochondrial pathways of apoptosis (Bouillet et al., 2002;
Janssens et al., 2003). Furthermore, TRAIL and FAS
receptor–ligand interactions, which commonly mediate the
activity of regulatory CD4+ T cells, were shown to play an
important role in spontaneous PBMC apoptosis in HIV-
infected patients (Badley et al., 1998; Lum et al., 2001). To
assess the role of apoptosis in the residual defect of CMI in
HAART recipients, we examined the correlations between
caspase activity and CMV-LPA and the effect of caspase
inhibitors on CMV-specific proliferation in HIV-infected
patients on HAART and uninfected controls.Results
HIV-infected patients on HAART have persistently high
levels of unstimulated PBMC apoptosis
The caspase 3 activity of unstimulated PBMC obtained
from 12 HAART recipients was significantly higher
compared with that of 11 uninfected controls (mean F SE
of 292 F 72 and 87 F 19 nmol/min/mg, respectively; P =
0.02, unpaired t test) (Fig. 1). Furthermore, caspases 8 and 9
activities in unstimulated PBMC from six HIV-infected
patients had mean F SE of 16 F 10 and 30 F 17 nmol/min/
mg, respectively, whereas caspase 8 or 9 activity was not
detected in unstimulated PBMC obtained from four healthy
controls (Fig. 1).
To characterize the cells responsible for the excess
apoptosis, we used annexin V binding assays. There was a
highly significant linear relationship between caspase activity
and annexin V binding of unstimulated PBMC (P = 0.004,
r2 = 0.88), indicating that both assays measured the same
biologic phenomenon. Furthermore, the percentage of total
PBMC that bound annexin V was significantly higher in
seven HIV-infected patients with HIV viral load (VL) b200
RNA copies/ml compared with six uninfected controls
(mean F SE of 40 F 5% vs. 18 F 2%, P = 0.005, unpaired
t test; Fig. 2). The excess apoptosis in patients was due to
increased percentage of apoptotic CD4+ T lymphocytes
(15 F 1% vs. 3 F 1%, P = 0.0008) and CD14+ monocytes(35 F 2% vs.16 F 2%, P = 0.002), but not of CD8+ T
lymphocytes (19 F 2% vs. 16F 3%, P = 0.41) or CD19+ B
lymphocytes (13 F 3% vs. 13 F 2%, P = 0.79). Taken
together, these data indicated that in spite of HAART and
undetectable viral replication, HIV-infected patients had
persistently increased levels of apoptosis of CD4+ and
CD14+ unstimulated PBMC.
Increased spontaneous apoptosis correlates with decreased
CMV-specific proliferation in HIV-infected patients on
HAART
Increased caspase 3 activity of unstimulated PBMC was
significantly associated with lower CMV-specific prolifer-
ative responses, measured by 3H-Thy incorporation, in 12
HIV-infected patients (P = 0.04; r2 = 0.37; Fig. 3A). In
contrast, an association between spontaneous apoptosis and
CMV LPA could not be demonstrated in eight uninfected
controls (P = 0.64; r2 = 0.03; Fig 3B).
Immunologic and virologic correlates of apoptosis and of
CMV-LPA
To determine if the association between CMV-specific
proliferation and apoptosis of unstimulated PBMC was
independent of HIV replication and CD4+ T cell depletion,
we examined the correlations of CMV-LPA and apoptosis
with HIV VL and CD4+ T cell counts in 12 HIV-infected
patients (Fig. 4). The data showed a lack of association
between caspase 3 activity and CD4 counts (P = 0.27; r2 =
0.12) and a significant increase of caspase 3 activity with
higher HIV VL (P = 0.008; r2 = 0.52). However, the
caspase 3 activity in unstimulated PBMC from seven HIV-
infected patients with undetectable HIV VL (b200 RNA
copies/ml) remained significantly higher when compared
with uninfected controls (mean F SE of 422 F 90 vs.
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Fig. 2. Phenotypic characterization of the cells responsible for excess
apoptosis of unstimulated PBMC from HAART recipients. Data were
derived from seven HIV-infected patients on HAART with HIV VL b200
copies/ml and six uninfected controls. Columns indicate mean and SEM.
Apoptosis of total PBMC, CD4+, and CD14+ cells was significantly
higher in HIV-infected patients compared with uninfected controls (un-
paired t test), whereas apoptosis of CD8+ and CD19+ lymphocytes were
not significantly different between groups.
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demonstrate an association between caspase 3 activity and
duration of HAART (linear correlation P = 0.33, r2 =
0.14) or specific drugs included in the ART. With respect
to lamivudine, which has been previously implicated in
increased PBMC apoptosis (de Oliveira Pinto et al., 2002),
the difference of caspase 3 activity in PBMC from three
patients on lamivudine-containing HAART compared with
nine patients on lamivudine-free HAART was 3.24 nmol/
min/mg (95% confidence interval = 207.27–200.78
nmol/min/mg; P = 0.97).
In contrast to apoptosis, CMV-specific proliferation was
significantly associated with CD4+ T cell counts (P = 0.03;
r2 = 0.41), but not with HIV VL (P = 0.21; r2 = 0.15).
Hence, proapoptotic factors other than HIV replication
probably contribute to the down regulatory effect of
spontaneous apoptosis on CMV LPA. Similarly, since there
was no significant association between CD4+ T cell counts
and spontaneous apoptosis, we conclude that the down
regulatory effect of apoptosis on CMV LPA is not due toFig. 3. Relationship between apoptosis of unstimulated PBMC and CMV-specific
(B). Data were derived from 11 HIV-infected donors and eight uninfected con
activity) in unstimulated PBMC and proliferation measured by 3H-thymidine in
infected patients only.CMV-specific T cell depletion, but rather involves a deficit
of T cell function.
Caspase 3 activity of CMV-stimulated PBMC increases with
proliferation
To further assess the contribution of apoptosis to CMV-
LPA down regulation in HIV-infected patients, we meas-
ured the caspase 3 activity in CMV-stimulated PBMC
cultures from HAART recipients and healthy controls.
Contrary to our expectations, the caspase 3 activity
increased with proliferation both in HIV-infected patients
(P = 0.002; r2 = 0.63) and in uninfected controls (P =
0.004; r2 = 0.46) (Fig. 5). This indicated that proliferation
constitutes a very potent stimulus of caspase 3 activity
obfuscating any preexisting differences between HIV-
infected patients and uninfected controls.
Effect of Inhibitors of apoptosis on PBMC proliferation
We studied the effect of biological and chemical
compounds, which disrupt the apoptotic cascade at different
steps (Table 1). To determine the effect of blocking agents
that interfere with signaling through the cell membrane
death receptors, CMV- and mock-stimulated PBMC cul-
tures were treated with anti-Fas L or with TRAIL R1/R2.
Results were compared with proliferation in untreated
cultures. We chose to block the ligands rather than the
receptors on the T cell surface in order to avoid partial
agonistic effects. The data showed that blocking the in vitro
interactions between these cell death receptors and their
cognate ligands did not affect proliferation of CMV-
stimulated (Table 1) or control-stimulated PBMC (data not
shown) of HIV-infected patients and uninfected controls.
The effect of caspase inhibitors on in vitro PBMC
proliferation was determined (Table 1). Pan-caspase,
caspase 3, and caspase 8 inhibition decreased proliferation
of CMV-stimulated PBMC of HIV-infected patients and
healthy individuals (P = 0.05 and 0.007 in HIV+ and
HIV individuals, respectively, for pan-caspase inhibition,
ANOVA for repeated measures; P b 0.001 and P =proliferation in HIV-infected patients on HAART (A) and healthy controls
trols. There was a significant relationship between apoptosis (caspase 3
corporation after 6 days of in vitro CMV antigenic stimulation in HIV-
Fig. 4. Immunologic (A and C) and virologic (B and D) correlates of CMV-specific proliferation (C and D) and apoptosis (A and B) of PBMC from HIV-
infected patients on HAART. Apoptosis of unstimulated PBMC measured by caspase 3 activity was significantly associated with HIV VL at the time when the
PBMC were collected (B) but not with CD4+ cell counts (A). In contrast, in vitro CMV-specific proliferation measured by 3H-thymidine incorporation was
significantly associated with CD4+ cell counts (C), but not with HIV VL (D).
Table 1
Differential effect of apoptosis inhibitors on CMV-specific PBMC
proliferation in HIV-infected patients and uninfected controls
Compound HIV infected Uninfected
Untreated Treated Untreated Treated
Anti-Fas L
(10 Ag/ml)
3.0 F 0.5a 2.9 F 0.6 4.5 F 0.3 4.7 F 0.2
A. Weinberg et al. / Virology 330 (2004) 313–3213160.005, respectively, for caspase 3 inhibition; and P = 0.05
and 0.005, respectively, for caspase 8 inhibition). Only
the caspase 3 inhibitor significantly decreased prolifer-
ation of mock-stimulated PBMC from either group of
subjects (data not shown). These data suggest that one or
more caspases play active roles in PBMC proliferation
and are consistent with the increase of caspase 3 activity
associated with antigen-driven PBMC proliferation shown
in Fig. 5. The down-regulatory effect of certain caspase
inhibitors on PBMC proliferation negates their utility in
the effort to unravel the interactions between apoptosis
and proliferation.
CrmA had the unique effect of significantly increasing
proliferation of CMV-stimulated PBMC from HIV-infectedFig. 5. Caspase 3 activity increases with proliferation of CMV-stimulated
PBMC both in HIV-infected patients on HAART (P = 0.002; r2 = 0.63) and
in uninfected controls (P = 0.004; r2 = 0.46).patients, but not from uninfected subjects (P values of 0.02
and 0.5, respectively). CrmA also increased proliferation in
mock-stimulated PBMC from HIV-infected subjects (P =
0.03), but not from healthy donors (P = 0.97). The increase
of CMV-specific proliferation of PBMC from HIV-infected
patients generated by in vitro treatment with 10 ng/ml ofTRAIL R1 and R2
(100 Ag/ml each)
2.0 F 0.2 2.0 F 0.2 4.9 F 0.1 5.0 F 0.1
Z-VAD.fmk
(100 AM)
3.2 F 0.9b 2.9 F 0.9 4.8 F 0.1 2.6 F 0.2
Anti-caspase 3
(30 AM)
3.6 F 0.6 1.4 F 0.1 4.7 F 0.2 1.6 F 0.1
Anti-caspase 8
(33 AM)
2.1 F 0.4 1.7 F 0.4 4.7 F 0.1 4.5 F 0.1
CrmA (10 ng/ml) 2.7 F 0.4c 3.2 F 0.3 3.7 F 1.0 3.9 F 0.7
a Data represent mean F SE of log10 CPM of CMV-stimulated PBMC
obtained from six donors. Multiple concentrations of the inhibitory
compounds were used but only one (indicated in parentheses) is denoted
in the table. The following drug concentrations were used in these
experiments: anti-Fas L at 1.1, 3.3, and 10 Ag/ml; TRAIL R1/R2 mixed
at 0/100, 100/0, and 100/100 Ag/ml; Z-VAD.fmk pan-caspase inhibitor at
50 and 100 AM; DEVD-CHO caspase 3 inhibitor at 3.3, 10, and 30 AM; Z-
IETD.fmk caspase 8 inhibitor at 11, 33, and 100 AM; and crmA at 0.1, 1,
and 10 ng/ml.
b Bold-faced figures indicate significant differences by ANOVA for
repeated measures (P V 0.05).
c Italics indicate significant proliferation increases in treated cultures.
A. Weinberg et al. / Virology 330 (2004) 313–321 317crmA was accompanied by a modest but significant
decrease in apoptosis measured by annexin V binding
from mean F SE of 41 F 6% in untreated cells to 36 F 6%
in the treated ones (P = 0.03). A significant effect of crmA
on PBMC apoptosis could not be demonstrated in unin-
fected controls (mean F SE of 25.7 F 6% vs. 23.3 F 4%,
P = 0.53). A correlation analysis between the crmA-
induced decrease of apoptosis and increase in CMV-
specific proliferation in PBMC cultures from HIV-infected
patients showed a marginally significant association (Fig. 6,
P = 0.07, r2 = 0.59).
The data showed that death cell receptor blockade did
not affect PBMC proliferation of HIV-infected patients, but
that crmA inhibition, which blocks the mitochondrial
pathway of apoptosis at the caspase 9 level (caspase 8
and others) in addition to the death cell receptor pathway,
increased proliferation. Furthermore, it indicated that
rescuing the PBMC from apoptosis partially corrected
their proliferation deficit.Discussion
Our data demonstrate that apoptosis of unstimulated
PBMC, which remains elevated in HIV-infected patients on
HAART, contributes to the persistence of functional
immunologic defects in HAART recipients. This conclusion
was supported by the observation that apoptosis of
unstimulated PBMC from HIV-infected patients was sig-
nificantly associated with decreased CMV-stimulated pro-
liferation and that crmA, which rescued PBMC from
apoptosis, increased proliferation in HAART recipients.
Furthermore, the cells responsible for excess PBMC apop-
tosis in HAART recipients with undetectable HIV VL, CD4+
T lymphocytes and CD14+ monocytes, play critical roles in
antigen-driven proliferation, providing a mechanistic explan-
ation for the association between apoptosis and decreased0.00
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Fig. 6. CrmA-associated decrease in apoptosis (delta % annexin V binding)
shows a marginally significant correlation with the increase in CMV-
specific proliferation of PBMC (delta log10 CMV CPM) in HIV-infected
patients on HAART.LPA. To our knowledge, this is the first demonstration that
persistently increased PBMC apoptosis has deleterious
consequences on the CMI of HAART recipients.
Although crmA treatment generated significant increases
of proliferation and decreases of apoptosis of CMV-
stimulated PBMC from HIV-infected patients, its effect
had modest amplitude. This effect, however, constitutes an
important proof that the proapoptotic stimuli may be
counterbalanced in HAART recipients and that other
immune modulators with more potent or more specific
antiapoptotic activity might generate more robust immune
reconstitution of HAART recipients. In addition, we did not
find a significant increase in proliferation of crmA-treated
PBMC from uninfected controls. A stimulatory effect of
crmA in uninfected controls might be more difficult to
demonstrate due to the intense proliferation induced by
CMV in untreated PBMC coupled with a modest effect of
crmA. The alternative explanation is that proapoptotic
stimuli limit proliferation of PBMC from HAART recipi-
ents but not from uninfected individuals, which is also
consistent with the excess apoptosis detected in unstimu-
lated PBMC from HIV-infected patients.
The down regulatory effect of PBMC apoptosis on CMV-
specific proliferation in HAART recipients was independent
of CD4 depletion. Although CMV LPA increased with
higher CD4 counts and decreased with higher spontaneous
caspase 3 activity, we did not find an association between
caspase 3 activity or CD4-annexin V binding (data not
sown) in PBMC from HIV-infected patients and their CD4+
T cell counts. These data suggest that the mechanism by
which apoptosis down regulates CMV-specific PBMC
proliferation does not involve depletion of CMV-specific
memory cells. The alternative explanation is functional
impairment of the apoptotic CD4+ memory cells and/or
CD14+ antigen presenting cells leading to decreased
proliferation. To the extent to which apoptosis could be
reversed or prevented, the functional deficits of CD4+ and
CD14+ cells might also be ameliorated.
To gain a better insight into the mechanisms that increase
apoptosis and decrease PBMC proliferation in HAART
recipients, we used inhibitors of apoptosis in our in vitro
experimental model. Our attempts to increase proliferation
by blocking the Fas/FasL and TRAIL/cognate receptors
interactions were unsuccessful. We chose these cell death
pathways because they have been previously shown to
contribute to increased apoptosis in HIV-infected patients
(Badley et al., 1998; Lum et al., 2001). Since these
manipulations were performed in vitro, our data do not
exclude the in vivo contributions of Fas and/or TRAIL
pathways to PBMC apoptosis. Nevertheless, these cell death
receptors seem to play a minor role in the down regulation
of antigen-driven PBMC proliferation.
Pan-caspase, as well as caspase-3- and caspase-8-specific
inhibition, decreased proliferation. Although this effect
seems paradoxical from the standpoint of inhibition of
apoptosis, it is consistent with previous observations (Alam
A. Weinberg et al. / Virology 330 (2004) 313–321318et al., 1999; Chun et al., 2002) that some caspases actively
participate in PBMC proliferation. An alternative explan-
ation consists of the possibility that these caspase inhibitors
might have a cross-reactive blocking effect against other
cellular proteases involved in proliferation. However, the
engagement of caspases in PBMC proliferation was also
supported by the fact that caspase 3 activity increased with
CMV-specific proliferation in HIV-infected patients and
uninfected controls.
Our data suggest that the mitochondrial pathway might
be involved in PBMC apoptosis and CMI down regulation
of HIV-infected patients on HAART. Caspase 9, which is
recruited into the apoptosis cascade downstream of the
mitochondrial membrane depolarization, was active in
unstimulated PBMC from HIV-infected patients on HAART
but not in uninfected controls. Furthermore, the crmA-
mediated inhibition of caspase 9, unlike the death cell
receptor blockade, led to modest but significant increases in
proliferation and decreases in apoptosis of PBMC from
HAART recipients. More importantly, this effect was
specific for HIV-infected patients in the sense that it was
not reproduced in healthy controls.
Several mechanisms may activate apoptosis in HIV-
infected patients. Firstly, HIV replication has been asso-
ciated with recruitment of the mitochondrial apoptotic
pathway via overexpression of p53 (Genini et al., 2001). A
direct effect of HIV replication is supported by the
association of caspase 3 activity in unstimulated PBMC
with the HIV VL. However, CMV-specific proliferation
was not significantly associated with HIV VL, suggesting
that other proapoptotic factors, independent from HIV
replication, may contribute to the down regulation of T cell
function. Secondly, apoptosis and decreased proliferation
may occur as a consequence of insufficient T cell growth
cytokine production, which has been previously described
in HIV-infected patients (Adachi et al., 1996; Jaleco et al.,
2003; Zaunders et al., 2003). Thirdly, regulatory T cells
might be involved in this process. We have previously
shown that CD8+ T cell depletion increases CMV-specific
proliferation in HIV-infected patients (Weinberg et al.,
2001), which would be consistent with a CD8+ T cell
regulatory effect on proliferation (Cosmi et al., 2003;
Najafian et al., 2003). CD8+ regulatory cells might use
granzyme B-mediated cytotoxicity as an effector of their
suppressive activity. Granzyme B induces apoptosis
primarily through the mitochondrial pathway (Trapani
and Smyth, 2002) and its effect can be inhibited by crmA
(Quan et al., 1995). This last mechanism is also consistent
with our previous observations correlating activated CD8+
T cells with lack of antigen-driven proliferation in HIV-
infected children on HAART (Weinberg et al., 2004a). The
three potential CMI down regulatory mechanisms outlined
above are not mutually exclusive. Further studies are
warranted to elucidate their relative importance and
measures capable of reverting their effect on CMI of
HIV-infected patients.Subjects and methods
Subjects
This study enrolled 55 CMV-seropositive individuals
including 39 HIV-infected patients on HAART and 16
uninfected controls. Inclusion criteria for HIV-infected
patients were the following: HAART, defined as a z3 drug
regimen including z2 antiretroviral classes for z3 months;
CD4+ cell count b100 cells/Al before HAART; and z100
cells/Al when entered into the study. The median CD4+ cell
count of the HIV-infected patients in this study was 259
cells/Al and the maximum was 1504 cells/Al. The HIV VL
on study varied between b101.3 and N105.9 copies/ml with a
median of 102.6 copies/ml. The mean F SD time on
HAART was 39 F 22 months.
Monoclonal antibodies (MAb) and reagents
The MAb and reagents used in this study were as
follows: anti-human Fas Ligand (R&D Systems), APC-
conjugated anti-CD4, CD8, CD14, and CD19 (Pharmin-
gen), caspase inhibitor zVAD (Z-Val-Ala-Asp(OMe)-FMK
(Enzyme Systems Products), recombinant human TRAIL
R1/Fc Chimera and TRAIL R2/Fc Chimera (R&D Sys-
tems), caspase 3 inhibitor I DEVD-CHO (Calbiochem),
caspase 8 inhibitor Z-IETD-FMK (R&D Systems), and
crmA (Sigma), which inhibits caspase 9 and other caspases.
Specimen processing and cryopreservation
Peripheral blood mononuclear cells from heparinized
blood, separated by Ficoll/histopaque density gradient
centrifugation (Sigma), were counted and cryopreserved as
previously described (Weinberg et al., 2000). In brief,
PBMC were resuspended at 107 cells/ml in cold fetal bovine
serum (FBS, HyClone) with 10% dimethyl sulfoxide
(DMSO, Sigma). A Mr. Frosty freezing container (Fisher)
gradually brought the cells to 708C. After 24 h, the cells
were transferred to liquid nitrogen for long-term storage. For
use in assays, cells were removed from the liquid nitrogen
and thawed in 378C water bath until a small amount of cells
remained frozen. The slow addition of RPMI 1640 with
glutamine (Gibco) and 10% human type AB serum
completed the thawing process. Cells were washed twice
and resuspended 107/ml final concentration with RPMI
1640 with glutamine (Gibco).
Lymphocyte proliferation assay (LPA)
LPA was performed as previously described (Weinberg
et al., 2001). In summary, stimulation medium consisted of
RPMI 1640 with glutamine (Gibco), 10% human AB serum
(Nabi), and 1% antibiotics (Gibco). PBMC (105 cells/well)
were added to quadruplicate wells containing CMVantigen,
prepared as previously described (Weinberg et al., 1998), at
A. Weinberg et al. / Virology 330 (2004) 313–321 319a 1:200 final concentration. Mock-infected antigen and
pokeweed mitogen (Sigma) were used as negative and
positive controls at dilutions of 1:200 and 10 Ag/ml final,
respectively. MAbs and compounds used to modulate cell
proliferation were added to the stimulation medium in the
concentrations specified in the Results section. After 6 days
of culture at 378C in 5% CO2 atmosphere, cells were pulsed
with 3H-thymidine and their DNA was harvested 6 h later
onto unifilter plates (Perkin Elmer). Radioactivity gathered
on the filters was counted on a microplate scintillation
counter (Packard).
Caspase activity assays
The activity of caspases 3, 8, and 9 were determined by
use of fluorescent substrates as previously described
(Melnikov et al., 2001, 2002) with modifications. Two
million lymphocytes were mixed with a lysis buffer
containing 25 mM Na+ Hepes, 2 mM dithiothreitol (DTT),
1 mM EDTA, 0.1% 3-[(3-cholamidopropyl) dimethylam-
monio]-1-pro-panesulfonate (CHAPS), 10% sucrose, 1 mM
phenylmethylsulfonyl fluoride, and 1 AM pepstatin A, pH
7.2. The lysates were immediately frozen and stored at
708C until use. Lysate protein was measured by the Bio-
Rad Detergent Compatible (DC) protein assay kit with
bovine serum albumin as standards. The caspase assay was
performed on lysate as follows: 40 Al of lysate (50–100 Ag
protein) and 10 Al of the substrate (final concentration, 25
AM) were added to 150 Al caspase assay buffer. The assay
buffer for caspase 3 contained 250 mM K+ Hepes, 50 mM
KCl, 1 mM DTT, 1 mM EDTA, 0.1% CHAPS, pH 7.4. Ac-
Asp-Glu-Val-Asp-7-amido-4-methyl coumarin (Ac-DEVD-
AMC) in 10% DMSO was used as a susceptible substrate
for caspase 3 (Thornberry et al., 1997). The assay buffer for
caspases 8 and 9 contained 75 mM Na+ MOPS, 10%
glycerol, 1 mM DTT, 1 mM EDTA, pH 7.4. Ac-Ile-Glu-Pro-
Asp-7-Amino-4-methylcoumarin (IEPD-AMC) in 10%
DMSO was used as a susceptible substrate for caspase 8
(Autran et al., 1997). Ac-Leu-Glu-His-Asp-7-Amino-4-
methylcoumarin (LEHD-AMC) in 10% DMSO was used
as a susceptible substrate for caspase 9 (Autran et al., 1997).
The solution was preincubated for 10 min at 308C before
substrate was added. The reaction was then initiated by
addition of substrate. Peptide cleavage was measured over 1
h at 308C using a Cytofluor 4000 series fluorescent plate
reader (Perseptive Biosystems) at an excitation wavelength
of 380 nm and an emission wavelength of 460 nm. An
AMC standard curve was determined for each experiment.
Caspase activity was expressed in nmol of AMC released
per min of incubation time per mg of lysate protein.
Annexin V flow cytometry assay
TSCS annexin V-FITC apoptosis detection kit (R&D
Systems) was used for quantification of PBMC apoptosis.
Samples containing 1.0  105 to 1.0  106 PBMC werecentrifuged at 500 g for 10 min, washed with cold PBS,
centrifuged, and resuspended in 100 AL of Annexin V
Incubation Reagent containing Annexin V-FITC (100
final concentration) and propidium iodide (PI). After 15 min
of incubation in the dark, 400 AL of 1 binding buffer were
added. Samples were analyzed using a FACScan flow
cytometer (Becton Dickinson).
Statistical analysis
Statistical analysis was performed using Instat3 and
Prism software (Graph Pad) with a level of significance
established at P V 0.05. Distribution of results was checked
for normality and parametric tests were preferentially
applied when the data had a normal distribution.Acknowledgments
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